Maxim Group Downgrades Momenta Pharmaceuticals (MNTA) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BofA/Merrill Lynch Still Likes Risk-Reward on Momenta Pharmaceuticals (MNTA)
January 22, 2015 7:01 AM ESTBofA/Merrill Lynch analyst Sumant Kulkami reiterated a Buy rating and $14 price target on Momenta Pharmaceuticals (NASDAQ: MNTA) saying they still like the risk-reward despite a court ruling in favor of Teva on Copaxone.
The analyst notes the ruling itself... More
Momenta Phama (MNTA) Reports Vacation of CAFC Decision on Copaxone Patents
January 21, 2015 8:33 AM ESTMomenta Phama (Nasdaq: MNTA) announced that the United States Supreme Court has vacated the 2013 decision of the Court of Appeals for the Federal Circuit ("CAFC") which found several of the Copaxone (20 mg injection) patents, including the one patent expiring September 1, 2015, invalid for being indefinite. The Supreme Court has overturned the long standing practice whereby the CAFC reviewed a District Court's claim interpretation "de novo," without deference to the... More
